Search

A study published in Pediatric News compared the effectiveness of three cycles versus six cycles of chemotherapy for high-risk retinoblastoma. The research found that three cycles showed noninferior 5-year disease-free survival rates, with fewer adverse events and lower costs. The study, led by Huijing Ye, MD, PhD, was published in JAMA and could potentially impact clinical practice by reducing treatment burden and costs without compromising patient outcomes. [Extracted from the article]